Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Sold by HighTower Advisors LLC

HighTower Advisors LLC reduced its stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 26.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 79,636 shares of the company’s stock after selling 28,377 shares during the quarter. HighTower Advisors LLC owned about 0.09% of Aquestive Therapeutics worth $284,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Verition Fund Management LLC bought a new position in shares of Aquestive Therapeutics during the 3rd quarter valued at about $995,000. State Street Corp increased its holdings in Aquestive Therapeutics by 52.1% in the third quarter. State Street Corp now owns 1,496,739 shares of the company’s stock worth $7,454,000 after buying an additional 512,682 shares during the last quarter. Harvey Capital Management Inc. lifted its stake in shares of Aquestive Therapeutics by 1,419.3% in the 4th quarter. Harvey Capital Management Inc. now owns 267,390 shares of the company’s stock valued at $952,000 after purchasing an additional 249,790 shares during the last quarter. Wellington Management Group LLP acquired a new position in shares of Aquestive Therapeutics during the 3rd quarter valued at about $922,000. Finally, BNP Paribas Financial Markets lifted its stake in shares of Aquestive Therapeutics by 252.2% in the third quarter. BNP Paribas Financial Markets now owns 18,826 shares of the company’s stock worth $94,000 after buying an additional 13,481 shares during the last quarter. 32.45% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on AQST. Lake Street Capital dropped their price objective on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, March 7th. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Aquestive Therapeutics in a research report on Wednesday. Cantor Fitzgerald initiated coverage on shares of Aquestive Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $17.00 target price on the stock. Alliance Global Partners restated a “buy” rating on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Finally, Raymond James set a $7.00 target price on Aquestive Therapeutics in a research note on Friday, March 7th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $10.57.

Aquestive Therapeutics Stock Up 6.3 %

NASDAQ AQST opened at $3.04 on Thursday. The stock has a fifty day simple moving average of $2.98 and a 200 day simple moving average of $3.91. The company has a market capitalization of $300.57 million, a price-to-earnings ratio of -6.76 and a beta of 2.76. Aquestive Therapeutics, Inc. has a twelve month low of $2.24 and a twelve month high of $5.80.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The firm had revenue of $11.87 million for the quarter, compared to analysts’ expectations of $13.11 million. Research analysts expect that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.